Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

NCT00884312 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00884312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00884312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm, Phase 2 Study of Extended Carfilzomib Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
April 9, 2009
Completion date
May 17, 2017
Enrollment
101 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, solid tumors